1. Anti-infection
  2. Bacterial

RNAIII-inhibiting peptide(TFA) 

Cat. No.: HY-P1452A Purity: 99.86%
Handling Instructions

RNAIII-inhibiting peptide(TFA) is a potent inhibitor of Staphylococcus aureus, effective in the diseases such as cellulitis, keratitis, septic arthritis, osteomylitis and mastitis. Sequence: Tyr-Ser-Pro-Trp-Thr-Asn-Phe;YSPWTNF.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

RNAIII-inhibiting peptide(TFA) Chemical Structure

RNAIII-inhibiting peptide(TFA) Chemical Structure

Size Price Stock Quantity
1 mg USD 210 In-stock
Estimated Time of Arrival: December 31
5 mg USD 630 In-stock
Estimated Time of Arrival: December 31
10 mg   Get quote  
50 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

RNAIII-inhibiting peptide(TFA) is a potent inhibitor of Staphylococcus aureus, effective in the diseases such as cellulitis, keratitis, septic arthritis, osteomylitis and mastitis. Sequence: Tyr-Ser-Pro-Trp-Thr-Asn-Phe;YSPWTNF.

IC50 & Target

Staphylococcus aureus[1]

In Vitro

RNAIII-inhibiting peptide(TFA) is a potent inhibitor of Staphylococcus aureus. RNAIII-inhibiting peptide (RIP) inhibits the synthesis of both RNAII and RNAIII, while RAP activates in wild type S. aureus cells. RNAIII-inhibiting peptide (5 μg/106 cells) potently reduces bacterial cell adhesion to HEp2 cells in the absence of serum, but with slight overall reduction the presence of serum. RNAIII-inhibiting peptide inhibits while RAP induces the phosphorylation of TRAP[1].

In Vivo

RNAIII-inhibiting peptide (20 mg/kg, i.v.) decreases lethality in mice challenged with S. aureus ATCC 25923, with the lethality rate of 70%, and when combined with cefazolin, imipenem, vancomycin, the rates are 20%, 15% and 10%. RNAIII-inhibiting peptide (20 mg/kg, i.v.) also causes decreased lethality in mice challenged with S. aureus Smith, with the lethality rate of 75%, and the lethality rate decreases to 30%, 10% and 10% when combined with cefazolin, imipenem, vancomycin[2].

Solvent & Solubility
In Vitro: 

DMSO : ≥ 150 mg/mL (146.06 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 0.9737 mL 4.8685 mL 9.7370 mL
5 mM 0.1947 mL 0.9737 mL 1.9474 mL
10 mM 0.0974 mL 0.4869 mL 0.9737 mL
*Please refer to the solubility information to select the appropriate solvent.
References
Animal Administration
[2]

Mice[2]
Mice are randomized to receive intravenously isotonic sodium chloride solution (controls C1 and C2) and 20 mg/kg RNAIII-inhibiting peptide alone or combined with 20 mg/kg cefazolin, 10 mg/kg imipenem, or 10 mg/kg vancomycin. Animals are returned to individual cages and monitored for 7 days. The endpoints of the study are quantitative plasma bacterial evaluation and lethality. For each animal model, toxicity is evaluated on the basis of the presence of any drug-related adverse effects, i.e. local signs of inflammation, anorexia, weight loss, vomiting, diarrhea, fever, and behavioral alterations. In particular, to evaluate the physiological effects of RNAIII-inhibiting peptide, temperature, pulse, blood pressure, respirations and oxygenation are monitored in a supplementary RNAIII-inhibiting peptide-treated group without infection[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References
Molecular Weight

1027.01

Formula

C₄₇H₅₇F₃N₁₀O₁₃

Storage
Powder -80°C 2 years
  -20°C 1 year
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number *

 

Organization name *

Country or Region *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
RNAIII-inhibiting peptide(TFA)
Cat. No.:
HY-P1452A
Quantity:

RNAIII-inhibiting peptide(TFA)

Cat. No.: HY-P1452A